InfuSystems Holdings Inc (INFU)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • AMEX
Market Cap: $294.89M
Last updated: Nov 17, 2026 at 11:05 AM ET
InfuSystems Holdings Inc (INFU) Earnings: Report Dates and Results
InfuSystems Holdings (INFU) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, InfuSystems Holdings reported EPS of $0.20, above the $0.12 estimate. It beat the EPS estimate in each of the last 9 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
INFU has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 60.0% above the $0.10 reported for the quarter ended Dec 31, 2025.
INFU Earnings Call
The latest INFU earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 27 quarters below that had an estimate, INFU beat 14, missed 11 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $37.59M, up 3.0% from $36.49M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.20 | $0.12 | $0.12 - $0.12 | +66.67% | Beat | +33.3% | 1 | 1 up, 0 down | Nov 5, 2026 | $37.59M |
| Jun 30, 2026 | $0.15 | $0.12 | $0.09 - $0.12 | +25.00% | Beat | 0.0% | 4 | 0 up, 1 down | Aug 4, 2026 | $36.93M |
| Mar 31, 2026 | $0.05 | $0.03 | -$0.01 - $0.06 | +66.67% | Beat | -50.0% | 5 | 2 up, 2 down | May 7, 2026 | $33.68M |
| Dec 31, 2025 | $0.10 | $0.07 | $0.05 - $0.11 | +42.86% | Beat | +41.8% | 5 | 1 up, 0 down | Feb 24, 2026 | $36.23M |
| Sep 30, 2025 | $0.15 | $0.05 | $0.05 - $0.05 | +200.00% | Beat | +15.4% | 1 | 1 up, 0 down | Nov 4, 2025 | $36.49M |
| Jun 30, 2025 | $0.15 | $0.04 | $0.04 - $0.04 | +275.00% | Beat | +400.0% | 1 | 0 up, 1 down | Aug 5, 2025 | $36.00M |
| Mar 31, 2025 | $0.10 | -$0.03 | -$0.03 - -$0.03 | +433.33% | Beat | N/A | 1 | 0 up, 1 down | May 8, 2025 | $34.72M |
| Dec 31, 2024 | $0.07 | $0.06 | $0.06 - $0.06 | +17.50% | Beat | +2036.4% | 1 | 0 up, 1 down | Mar 4, 2025 | $33.85M |
| Sep 30, 2024 | $0.13 | $0.05 | $0.05 - $0.08 | +160.00% | Beat | +85.7% | 4 | 0 up, 0 down | Nov 7, 2024 | $35.32M |
| Jun 30, 2024 | $0.03 | $0.04 | $0.03 - $0.04 | -25.00% | Miss | 0.0% | 3 | 0 up, 0 down | Aug 8, 2024 | $33.70M |
| Mar 31, 2024 | -$0.05 | $0.01 | -$0.01 - $0.05 | -600.00% | Miss | N/A | 3 | 0 up, 0 down | May 9, 2024 | $32.00M |
| Dec 31, 2023 | $0.00 | $0.02 | -$0.02 - $0.02 | -83.50% | Miss | -67.0% | 2 | 0 up, 0 down | Mar 14, 2024 | $31.77M |
| Sep 30, 2023 | $0.07 | $0.09 | N/A | -22.22% | Miss | +133.3% | 3 | 0 up, 0 down | Nov 7, 2023 | $31.91M |
| Jun 30, 2023 | $0.03 | $0.08 | N/A | -62.50% | Miss | N/A | 3 | 0 up, 0 down | Aug 3, 2023 | $31.73M |
| Mar 31, 2023 | -$0.01 | $0.06 | N/A | -116.67% | Miss | N/A | 3 | 0 up, 0 down | May 4, 2023 | $30.37M |
| Dec 31, 2022 | $0.01 | $0.04 | $0.03 - $0.06 | -75.00% | Miss | -50.0% | 3 | 1 up, 0 down | Mar 15, 2023 | $28.83M |
| Sep 30, 2022 | $0.03 | $0.01 | -$0.01 - $0.02 | +200.00% | Beat | N/A | 3 | 0 up, 0 down | Nov 8, 2022 | $27.28M |
| Jun 30, 2022 | -$0.01 | -$0.01 | -$0.03 - $0.01 | 0.00% | In line | -120.0% | 3 | 0 up, 0 down | Aug 4, 2022 | $27.04M |
| Mar 31, 2022 | -$0.02 | -$0.03 | -$0.05 - $0.00 | +33.33% | Beat | -166.7% | 3 | 0 up, 0 down | May 5, 2022 | $26.76M |
| Dec 31, 2021 | $0.02 | $0.07 | $0.00 - $0.14 | -71.43% | Miss | -95.9% | 4 | N/A | Feb 10, 2022 | $26.52M |
| Sep 30, 2021 | -$0.02 | $0.01 | -$0.02 - $0.06 | -300.00% | Miss | -114.3% | 4 | 0 up, 0 down | Nov 15, 2021 | $26.57M |
| Jun 30, 2021 | $0.05 | $0.07 | $0.04 - $0.13 | -28.57% | Miss | -75.0% | 4 | N/A | Aug 12, 2021 | $24.83M |
| Mar 31, 2021 | $0.03 | $0.05 | $0.02 - $0.06 | -40.00% | Miss | N/A | 4 | N/A | May 6, 2021 | $24.46M |
| Dec 31, 2020 | $0.49 | $0.06 | $0.03 - $0.08 | +716.67% | Beat | +1125.0% | 3 | N/A | Mar 17, 2021 | $24.71M |
| Sep 30, 2020 | $0.14 | $0.04 | $0.02 - $0.05 | +250.00% | Beat | +180.0% | 2 | N/A | Nov 12, 2020 | $25.13M |
| Jun 30, 2020 | $0.20 | $0.02 | $0.02 - $0.02 | +900.00% | Beat | +900.0% | 1 | N/A | Aug 13, 2020 | $26.00M |
| Mar 31, 2020 | -$0.02 | -$0.02 | N/A | 0.00% | In line | N/A | N/A | N/A | May 14, 2020 | $21.55M |
| Dec 31, 2019 | $0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 19, 2020 | $21.71M |
| Sep 30, 2019 | $0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2019 | $21.49M |
| Jun 30, 2019 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2019 | $19.72M |
| Mar 31, 2019 | -$0.05 | N/A | N/A | N/A | N/A | -600.0% | N/A | N/A | May 14, 2019 | $18.19M |
| Dec 31, 2018 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 7, 2019 | $17.56M |
| Sep 30, 2018 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2018 | $16.68M |
| Jun 30, 2018 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2018 | $16.41M |
| Mar 31, 2018 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 24, 2018 | $16.48M |
| Dec 31, 2017 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 13, 2018 | $18.89M |
| Sep 30, 2017 | -$0.01 | N/A | N/A | N/A | N/A | -516.7% | N/A | N/A | Nov 10, 2017 | $17.59M |
| Jun 30, 2017 | -$0.05 | N/A | N/A | N/A | N/A | -857.6% | N/A | N/A | Aug 9, 2017 | $16.94M |
| Mar 31, 2017 | -$0.07 | N/A | N/A | N/A | N/A | -3988.9% | N/A | N/A | May 11, 2017 | $17.65M |
| Dec 31, 2016 | -$0.02 | N/A | N/A | N/A | N/A | -123.9% | N/A | N/A | Mar 22, 2017 | $16.85M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.50, up 177.0% from the year before. It was -$0.01 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.50 | +177.0% |
| Dec 31, 2024 | $0.18 | +93.5% |
| Dec 31, 2023 | $0.09 | +833.0% |
| Dec 31, 2022 | $0.01 | -87.5% |
| Dec 31, 2021 | $0.08 | -90.1% |
| Dec 31, 2020 | $0.81 | +1250.0% |
| Dec 31, 2019 | $0.06 | N/A |
| Dec 31, 2018 | -$0.05 | N/A |
| Dec 31, 2017 | -$0.17 | N/A |
| Dec 31, 2016 | -$0.01 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 4,000 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 4,004 | 8 | |
| 2025Q4 | Dec 31, 2025 | 3,898 | 9 | |
| 2025Q3 | Sep 30, 2025 | 4,390 | 8 | |
| 2025Q2 | Jun 30, 2025 | 4,459 | 8 | |
| 2025Q1 | Mar 31, 2025 | 4,605 | 9 | |
| 2024Q4 | Dec 31, 2024 | 5,180 | 9 | |
| 2024Q3 | Sep 30, 2024 | 5,712 | 10 | |
| 2024Q2 | Jun 30, 2024 | 4,570 | 8 |
2026Q1 Earnings Call
Opening remarks
Glen Akselrod Investor Relations Good morning, and thank you for joining us today to review InfuSystem's First Quarter 2026 Financial Results ended March 31, 2026. With us today on the call are Carrie Lachance, Chief Executive Officer; and Barry Steele, Chief Financial Officer. After the conclusion of today's prepared remarks, we will open the call for questions. Before we begin with prepared remarks, I would like to remind everyone certain statements made by the management team of InfuSystem during this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Except for statements of historical fact, this conference call may contain forward-looking statements that involve risks and uncertainties, some of which are detailed under the Risk Factors in the documents filed by the company with the Securities and Exchange Commission, including the annual report on Form 10-K for the year ended December 31, 2025. Forward-looking statements speak only as of the date the statements were made. The company can give no assurance that such forward-looking statements will prove to be correct. InfuSystem does not undertake and specifically disclaims any obligation to update any forward-looking statements, except as required by law. Now I'd like to turn the call over to Carrie Lachance, Chief Executive Officer of InfuSystem. Carrie?
Carrie Lachance Chief Executive Officer Thank you, Glen, and good morning, everyone. Welcome to InfuSystem's First Quarter Fiscal Year 2026 Earnings Call. Thank you all for joining us today. I will provide a first quarter overview, highlighting key initiatives and updating our progress on strategic priorities. Then Barry will provide a detailed summary of our financial results. I will then come back with some closing comments before opening the line to questions. Today, we reported first quarter of 2026 revenue of $33.7 million. This represented a decline from our prior year of just over $1 million on a GAAP basis, but a 1.7% increase on a pro forma basis. The GAAP reduction was mainly driven by the restructuring of our biomedical services contract with GE Healthcare, which reduced revenue by $1.6 million during the first quarter and is the basis for the adjustment to provide pro forma revenue. As we reported on our last two earnings calls, this restructuring improves our earnings because it allowed for an even larger reduction in direct contract expenses. Despite the decline in revenue, we generated approximately $6.4 million in adjusted EBITDA this quarter, roughly in line with the prior year, resulting in a modest improvement in adjusted EBITDA margin to 18.9%, up from 18.2% in the first quarter last year. Behind these results are two very important initiatives that warrant the progress update. First, we continue to expand our wound care product category.
Frequently Asked Questions About INFU
When is InfuSystems Holdings's next earnings date?
InfuSystems Holdings's next earnings report is expected for Feb 22, 2027.
Did INFU beat earnings estimates last quarter?
Yes. InfuSystems Holdings reported EPS of $0.20 for the quarter ended Sep 30, 2026, above the $0.12 estimate, a 66.67% surprise.
What EPS do analysts expect from INFU next quarter?
The consensus EPS estimate for InfuSystems Holdings for the quarter ending Dec 31, 2026 is $0.16 from 5 analysts, with estimates from $0.13 to $0.18.
How often does INFU beat earnings estimates?
InfuSystems Holdings beat the EPS estimate in each of the last 9 quarters, with an average surprise of +143.00%.
INFU pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors